AAVLife: Another Gene Therapy Effort To Treat Friedreich's Ataxia
This article was originally published in Start Up
Executive Summary
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.
You may also be interested in...
Atlas-Backed Firm Will Seek Pan-Ataxia Therapy With Biogen’s Assistance
Biogen participates with Atlas Venture in a $17 million Series A financing for Ataxion, which will seek to advance preclinical ion channel modulators for hereditary ataxias.
Voyager Lifts Off With $45M From Third Rock Ventures
The venture firm’s latest incubated project is a gene therapy start-up targeting CNS disorders. Voyager hopes to have three programs in the clinic by early 2017, targeting Parkinson’s, ALS and Friedreich’s ataxia.
With AAVLife Debut, Another Gene Therapy Effort To Treat Friedreich's Ataxia
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.